Expertise in
9
conditions

Dr. Shalini S. Shenoy

Pediatric Hematology Oncology
1 Childrens Pl, Div Ped Hematology And Onc, 
Saint Louis, MO 
Clinical Trials:Currently Recruiting for 2 Trials
36 Years of Experience
Expertise in
9
conditions
1 Childrens Pl, Div Ped Hematology And Onc, 
Saint Louis, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Shalini Shenoy is a Pediatric Hematologist Oncology provider in Saint Louis, Missouri. Dr. Shenoy has been practicing medicine for over 36 years is highly rated in 9 conditions, according to our data. Her top areas of expertise are Hemoglobinopathy, Hemolytic Anemia, Sickle Cell Disease, Congenital Hemolytic Anemia, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 114 peer reviewed articles and participating in 19 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatrics in MO
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 3 Less Insurance Carriers -

Locations

1 Childrens Pl, Div Ped Hematology And Onc, Saint Louis, MO 63110

Additional Areas of Focus

Dr. Shenoy has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

19 Clinical Trials

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Enrollment Status: Recruiting
Publish Date: October 10, 2025
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Busulfan, Carboplatin, Cisplatin, Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Etoposide Phosphate, Isotretinoin, Melphalan Hydrochloride, Sargramostim, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
Study Phase: Phase 3
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: April 17, 2025
Intervention Type: Drug
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant in Children and Adults
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant in Children and Adults
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Procedure, Drug
Study Drug: CIML NK Cell Infusion
Study Phase: Phase 1/Phase 2
Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure Diseases
Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure Diseases
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Phase: Phase 2
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Enrollment Status: Completed
Publish Date: August 19, 2025
Intervention Type: Other
Study Phase: Not Applicable
Familial Haploidentical T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease (IND 14359)
Familial Haploidentical T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease (IND 14359)
Enrollment Status: Active_not_recruiting
Publish Date: August 08, 2025
Intervention Type: Drug
Study Drug: CD34-Positive T Cell-Depleted Allogeneic Stem Cell Transplant
Study Phase: Phase 2
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
Enrollment Status: Completed
Publish Date: February 27, 2025
Intervention Type: Procedure, Drug
Study Drugs: Azacitidine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Hydrocortisone, Leucovorin, Mercaptopurine, Methotrexate, PEG-Asparaginase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 2
Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial
Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial
Enrollment Status: Completed
Publish Date: July 17, 2024
Intervention Type: Drug
Study Drug: Abatacept
Study Phase: Phase 2
Anti-Angiogenic Therapy After Autologous Stem Cell Rescue (ASCR) for Pediatric Solid Tumors
Anti-Angiogenic Therapy After Autologous Stem Cell Rescue (ASCR) for Pediatric Solid Tumors
Enrollment Status: Completed
Publish Date: January 31, 2024
Intervention Type: Drug
Study Drugs: Metronomic Cyclophosphamide, Thalidomide
Study Phase: Phase 1
A Phase 1/2 Study of Cytokine-Induced Memory-Like NK Cells in Patients With AML or MDS
A Phase 1/2 Study of Cytokine-Induced Memory-Like NK Cells in Patients With AML or MDS
Enrollment Status: Terminated
Publish Date: January 17, 2024
Intervention Type: Procedure, Biological, Drug
Study Drugs: Fludarabine, Cyclophosphamide, ALT-803, Cytokine-Induced Natural Killer T Cells, IL-2
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed AML
A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed AML
Enrollment Status: Withdrawn
Publish Date: April 04, 2023
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cytokine induced memory-like NK cells, Fludarabine, Ara-C, G-CSF, Interleukin-2
Study Phase: Phase 2
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Enrollment Status: Unknown
Publish Date: February 08, 2023
A Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
A Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Enrollment Status: Completed
Publish Date: March 17, 2022
Intervention Type: Drug
Study Phase: Phase 3
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: November 26, 2021
Intervention Type: Radiation, Other, Drug
Study Phase: Phase 2
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Enrollment Status: Unknown
Publish Date: September 02, 2021
A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)
A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)
Enrollment Status: Unknown
Publish Date: November 12, 2020
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)
Enrollment Status: Enrolling_by_invitation
Publish Date: November 10, 2020
Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990 (RDCRN PIDTC-6904)
Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990 (RDCRN PIDTC-6904)
Enrollment Status: Completed
Publish Date: August 10, 2020
View 17 Less Clinical Trials

114 Total Publications

Excellent Outcomes in Feasibility Study of Radiation-free Conditioning and Transplant in Pediatric Severe Aplastic Anemia.
Excellent Outcomes in Feasibility Study of Radiation-free Conditioning and Transplant in Pediatric Severe Aplastic Anemia.
Journal: Transplantation and cellular therapy
Published: July 03, 2025
Similar Doctors
Expertise in
5
conditions
Dr. Melanie E. Fields
Pediatric Hematology Oncology
Expertise in
5
conditions
Dr. Melanie E. Fields
Pediatric Hematology Oncology
1 Childrens Pl, Div Ped Hematology And Onc, Ste 9s, 
Saint Louis, MO 
 (0.1 miles away)
314-454-6018
Languages Spoken:
English
See accepted insurances

Melanie Fields is a Pediatric Hematologist Oncology provider in Saint Louis, Missouri. Dr. Fields is highly rated in 5 conditions, according to our data. Her top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia.

Expertise in
16
conditions
Dr. William S. Ferguson
Pediatric Hematology Oncology
Expertise in
16
conditions
Dr. William S. Ferguson
Pediatric Hematology Oncology

Ssm Health Care Group

10101 Woodfield Ln, 
Saint Louis, MO 
 (7.9 miles away)
608-280-4647
Languages Spoken:
English
See accepted insurances

William Ferguson is a Pediatric Hematologist Oncology provider in Saint Louis, Missouri. Dr. Ferguson is highly rated in 16 conditions, according to our data. His top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Medulloblastoma, Ewing Sarcoma, and Bone Marrow Aspiration.

Expertise in
6
conditions
Dr. Allison A. King
Pediatric Hematology Oncology
Expertise in
6
conditions
Dr. Allison A. King
Pediatric Hematology Oncology

Washington University

1225 Graham Rd, 
Florissant, MO 
 (10.6 miles away)
314-545-2341
Languages Spoken:
English
See accepted insurances

Allison King is a Pediatric Hematologist Oncology provider in Florissant, Missouri. Dr. King is highly rated in 6 conditions, according to our data. Her top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Hemolytic Anemia, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shenoy's expertise for a condition
ConditionClose
    View All 22 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile